Categories: News

CORRECTION FROM SOURCE: CENTR Brands Corp. Announces Q2 2022 Results

While presented correctly in its Financial Statements and MD&A as filed on SEDAR, the date of the ending of Q2 2022 noted in the press release filed on January 28 2022 was incorrect. This error is corrected below in this amended press release.

Vancouver, British Columbia–(Newsfile Corp. – January 30, 2022) – CENTR Brands Corp. (CSE: CNTR) (FSE: 303) (OTCQB: CNTRF) (the “Company“) today announced its financial results for the quarter ended November 30, 2021. Selected comparative financial information is set forth below with the full financial statements for the quarter and the related management’s discussion and analysis (“MD&A“) available under the Company’s SEDAR profile at www.sedar.com. All amounts are expressed in United States Dollars, unless otherwise stated:

Q2
2022
Q2
2021
Gross sales 373,319 417,064
Net sales 298,799 317,845
Net income (loss) and comprehensive income (loss) for the period (1) 834,512 (752,354)
Basic and diluted income
(loss) per share
0.01 (0.01)

 

(1) Q2 2022’s net income and comprehensive income for the period includes non-cash gains of $2,320,419 for the revaluation of warrants as a liability for accounting purposes.

Consumers can visit CENTR’s online store at: www.findyourcentr.com/shop.

About CENTR Brands Corp.

CENTR Brands Corp. is one of North America’s leading functional beverage companies. CENTR develops and markets non-alcoholic, functional ingestibles for the global market. The Company produces CENTR and CENTR Sugar Free, both sparkling, low calorie, CBD beverages as well as CENTR Instant, a family of on-the-go CBD powders. For more information visit www.findyourcentr.com, and follow on Instagram at @findyourcentr.

For further information, contact media@findyourcentr.com.

On behalf of the Board,

CENTR BRANDS CORP.

/s/ Joseph Meehan
Joseph Meehan, Chief Executive Officer

This press release may contain “Forward-Looking Statements” within the meaning of applicable Canadian securities laws. Actual results may differ from those indicated as a result of finalization of the Company’s financial statements as well as other risks and uncertainties. Such statements represent the Company’s current views with respect to future events and are necessarily based upon a number of assumptions and estimates that, while considered reasonable by the Company, are inherently subject to significant business, economic, competitive, political and social risks, contingencies and uncertainties. Many factors, both known and unknown, could cause results, performance or achievements to be materially different from the results, performance or achievements that are or may be expressed or implied by such forward-looking statements. The Company does not intend, and does not assume any obligation, to update these forward-looking statements or information to reflect changes in assumptions or changes in circumstances or any other events affecting such statements and information other than as required by applicable laws, rules and regulations.

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/112095

Staff

Recent Posts

GE HealthCare Announces Cash Dividend for First Quarter of 2024

CHICAGO--(BUSINESS WIRE)--The Board of Directors of GE HealthCare Technologies Inc. (Nasdaq: GEHC) today declared a…

1 hour ago

GE HealthCare to Feature Latest Technologies in Interventional Radiology Focused on Precision Care at SIR 2024

Multi-modality showcase brings hands-on experience to care delivery for a wide range of vascular diseases…

1 hour ago

Smartsheet Names Katie Rooney to Board of Directors

Experienced global CFO adds depth in financial strategy and operating excellence to Smartsheet boardBELLEVUE, Wash.--(BUSINESS…

1 hour ago

The Centers for Medicare & Medicaid Services Revise National Coverage Determination for Stem Cell Transplantation

The Centers for Medicare & Medicaid Services revise the National Coverage Determination of allogeneic hematopoietic…

1 hour ago

Cocrystal Pharma Receives Pre-IND Responses from the FDA on Oral CC-42344 for Treating Influenza A

Feedback provides greater clarity on regulatory requirements for planned Phase 2b trial BOTHELL, Wash. (March…

2 hours ago